ArticleAdvances in therapy2026

Safety and Tolerability of Nintedanib in Japanese Patients with Progressive Fibrosing Interstitial Lung Diseases: Final Results of 2-Year Post-Marketing Surveillance.

Tomohiro Ito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.